Data from a recently published meta-analysis showed that administrating tenofovir in the second or third trimester of pregnant women with hepatitis B and high HBV DNA levels was safe and tolerable for both mother and child, and can prevent viral transmission when combined with HBV immunoglobulin and vaccine.
“Majority of worldwide guidelines recommend tenofovir as the preferred choice for [mother-to-child transmission] prevention in terms of anti-viral potency, available safety data during pregnancy and concerns for resistance compared to other anti-viral agents. To date, a small number of case series and relatively well-designed non-randomized controlled trails … using tenofovir have been conducted,” the researchers wrote. “However, since there is only one [randomized control trial] currently available, there are still concerns whether [one] provides sufficient evidence to disregard all the other [non-randomized control trials].”
The researchers reviewed the PubMed, EMBASE and Cochrane databases from inception to Aug. 16, 2016, for cases that included data on tenofovir use in pregnant women with HBV during the second or third trimester and control comparisons. The meta-analysis included 10 studies — one randomized control trial, four non-randomized control trials and five case studies — with a total of 733 patients. The randomized and non-randomized control trials had comparable data.